Seegene, Samsung Enter Cancer MDx Pact | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Seegene and Samsung Medical Center today said they will collaborate to develop new molecular diagnostics tests directed at cancer.

The partnership combines Seegene's MDx technology with Samsung's clinical and disease pathology expertise, the two firms said. They added that Samsung will provide the first test sites for the diagnostic products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.